Choix du traitement immunosuppresseur : 2 cas cliniques et

More documents

Recommendations

Info

100 % patients 0 PATIENT AND GRAFT SURVIVAL Simulect Thymoglobuline 98 % 100 % 100 % 94 % Patient survival Graft survival Y Lebranchu AJT 2002
50 40 30 20 10 0 ACUTE REJECTIONS OVER 6 MONTHS % of patients 8 % Treated Biopsy confirmed 12 % 8 % I I II II Simulect Thymoglobuline Y Lebranchu AJT 2002
Page 1 and 2: QUELS TRAITEMENTS IMMUNOSUPPRESSEUR
Page 3 and 4: Bilan prégreffe • Immunologie -
Page 5 and 6: • Pulmonaire - Primoinfection tub
Page 7 and 8: HOMEOSTASIE ET AGE J GORONZY Curr.
Page 9 and 10: • Donneur Greffe rénale préempt
Page 11: + + Simulect : 20 mg day 0 and day
Page 15 and 16: Meta-analysis of RCT comparing IL2R
Page 17 and 18: Delayed Graft Functiion (DGF) Acute
Page 20 and 21: En analyse multivariée OR 95% IC P
Page 22 and 23: Simulect ou absence de traitement d
Page 24 and 25: Simulect ® in Triple Therapy with
Page 26 and 27: CYCLOSPORINE OU TACROLIMUS?
Page 28 and 29: Biopsy Proven Acute Rejection (ITT,
Page 30 and 31: Graft survival (%) Graft and Patien
Page 32 and 33: Group A n=71 Sirolimus (SRL) Load:
Page 34 and 35: ml/min SRL CsA 60 50 40 30 51,8 ±1
Page 36 and 37: Cyclosporine ou Belatacept?
Page 39 and 40: LEA29Y* CsA (7±3 mg/kg daily)* LEA
Page 41: Median Iohexol clearance (ml/min/1.
Page 44 and 45: Cellcept ou Azathioprine?
Page 46 and 47: Graft survival (%) 100 95 90 85 80
Page 48 and 49: STEROIDES OU NON?
Page 50 and 51: Immunosuppression sans corticoïdes
Page 52 and 53: R Tac 0.1mg/kg MMF 1g Dac 1mg/kg St
Page 54: Adverse events Tac+MMF (N=260) % Ta
Page 62:
Evolution • Reprise normale de la
Page 65:
CINETIQUE DES SOUS-POPULATIONS T CD
show all

Choix du traitement immunosuppresseur : 2 cas cliniques et

Create successful ePaper yourself

Delete template?

Save as template?